PRPH2

Across TCGA pan-cancer cohorts, PRPH2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PRPH2 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher PRPH2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PRPH2 expression acts as an unfavorable survival marker.

BLCA, LUAD, and ESCA are the cancer types where PRPH2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.219	0.620	.010	18	view →
LUAD	DFS	Median	All	0.193	0.770	.004	9	view →
ESCA	OS	Median	II,III,IV	0.248	0.686	.019	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
COAD	DFS	Median	II,III,IV	0.140	0.743	.006	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PRPH2–BLCA (OS)

Open the BLCA breakdown →